Antibiotic prophylaxis for onabotulinum toxin A injections: systematic review and meta-analysis.

International urogynecology journal 2024 Vol.35(1) p. 19-29

Getaneh FW, Simhal R, Sholklapper T, Melvin E, Dorris CS, Chou J, Richter LA, Dieter A

관련 도메인

Abstract

[INTRODUCTION AND HYPOTHESIS] To our knowledge, there are no evidence-based recommendations regarding the optimal prophylactic antibiotic regimen for intradetrusor onabotulinum toxin type A (BTX) injections. This systematic review and meta-analysis was aimed at investigating the optimal prophylactic antibiotic regimen to decrease urinary tract infection (UTI) in patients undergoing BTX for overactive bladder syndrome (OAB).

[METHODS] A systematic search of MEDLINE, Embase, CINAHL, and Web of Science was conducted from inception through 30 June 2022. All randomized controlled trials and prospective trials with > 20 subjects undergoing BTX injections for OAB in adults that described prophylactic antibiotic regimens were included. Meta-analysis performed to assess UTI rates in patients with idiopathic OAB using the inverse variance method for pooling.

[RESULTS] A total of 27 studies (9 randomized controlled trials, 18 prospective) were included, representing 2,100 patients (69% women) with 19 studies of idiopathic OAB patients only, 6 of neurogenic only, and 2 including both. No studies directly compared antibiotic regimens for the prevention of UTI. Included studies favor the use of antibiotics in patients with idiopathic OAB and favor continuing antibiotics for 2-3 days after the procedure for prevention of UTI. Given the heterogeneity of the data, direct comparisons of antibiotic type or duration could not be performed. Meta-analysis found a 10% UTI rate at 4 weeks and 15% at 12 weeks post-injection.

[CONCLUSIONS] Although there are insufficient data to support the use of a specific antibiotic regimen, available studies favor the use of prophylactic antibiotics for 2-3 days in idiopathic OAB patients undergoing BTX injection. Future trials are needed to determine the optimal regimens to prevent UTI in patients undergoing BTX for OAB.

추출된 의학 개체 (NER)

유형영어 표현한국어 / 풀이UMLS CUI출처등장
해부 urinary tract scispacy 1
해부 bladder scispacy 1
합병증 infection 감염 dict 1
약물 onabotulinum toxin A scispacy 1
약물 [INTRODUCTION AND HYPOTHESIS] scispacy 1
약물 intradetrusor onabotulinum toxin type A scispacy 1
약물 OAB → overactive bladder syndrome scispacy 1
약물 CINAHL scispacy 1
약물 [RESULTS] A scispacy 1
약물 [CONCLUSIONS] scispacy 1
질환 urinary tract infection C0042029
Urinary tract infection
scispacy 1
질환 UTI → urinary tract infection C0042029
Urinary tract infection
scispacy 1
질환 overactive bladder syndrome C4020898
Overactive bladder syndrome
scispacy 1
질환 OAB → overactive bladder syndrome C4020898
Overactive bladder syndrome
scispacy 1
질환 idiopathic OAB scispacy 1
질환 BTX scispacy 1
기타 patients scispacy 1
기타 BTX scispacy 1
기타 UTI → urinary tract infection scispacy 1

MeSH Terms

Adult; Humans; Female; Male; Antibiotic Prophylaxis; Prospective Studies; Botulinum Toxins, Type A; Anti-Bacterial Agents; Urinary Tract Infections; Urinary Bladder, Overactive

🔗 함께 등장하는 도메인

이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들

관련 논문